The company's mission is to utilize blood-borne miRNAs to analyze the immune system's response to disease, enabling the development of innovative disease screening, diagnostics, and prognostics. They focus on developing liquid biopsy technology and disease-specific biomarkers to provide tailored treatment options and lifetime monitoring for patients. Founded in 2017, Hummingbird Diagnostics aims to deliver immediate value and actionable clinical guidance to healthcare providers, particularly in the selection of late-stage NSCLC patients who would benefit from immunotherapies.